Viking Therapeutics (VKTX) News Today $32.65 +0.09 (+0.28%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Viking Therapeutics: The Turning Point Is Not Here YetJanuary 20 at 4:56 PM | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Given Buy Rating at HC WainwrightJanuary 20 at 2:20 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Down 4.8% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Trading Down 4.8% - What's Next?January 18 at 2:21 PM | marketbeat.comShelton Wealth Management LLC Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Shelton Wealth Management LLC purchased a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 22,199 shares of the biotechnology company'sJanuary 18 at 9:53 AM | marketbeat.comNovo Nordisk data boosts H.C. Wainwright confidence in Viking’s potentialJanuary 17 at 7:33 PM | markets.businessinsider.comViking Therapeutics’ VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy ProfileJanuary 17 at 7:33 PM | markets.businessinsider.comViking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a research note on Friday.January 17 at 12:59 PM | marketbeat.comWhy Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped TodayJanuary 17 at 11:37 AM | fool.comViking Therapeutics (NASDAQ:VKTX) Sees Strong Trading Volume - What's Next?Viking Therapeutics (NASDAQ:VKTX) Sees Unusually-High Trading Volume - Here's WhyJanuary 16, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 4.8% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Shares Down 4.8% - Should You Sell?January 16, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 14, 2025 | prnewswire.comWhy Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on TuesdayJanuary 14, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Sees Large Volume Increase - Still a Buy?Viking Therapeutics (NASDAQ:VKTX) Sees Unusually-High Trading Volume - Still a Buy?January 14, 2025 | marketbeat.comInternational Assets Investment Management LLC Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)International Assets Investment Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 98.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,276 shares ofJanuary 10, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Given "Buy" Rating at HC WainwrightJanuary 10, 2025 | americanbankingnews.comAnalysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $106.75January 10, 2025 | americanbankingnews.comPositive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program AdvancesJanuary 9, 2025 | markets.businessinsider.comViking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy RatingJanuary 9, 2025 | markets.businessinsider.com3 Mid-Cap Stocks That Could Take Off in 2025January 9, 2025 | fool.comPositive Outlook for Viking Therapeutics Amid Promising Trial DevelopmentsJanuary 8, 2025 | markets.businessinsider.comViking Therapeutics’ oral-2735 could differentiate asset, says JPMorganJanuary 8, 2025 | markets.businessinsider.comViking Therapeutics initiates Phase 2 VENTURE-oral dosing trial of VK2735January 8, 2025 | markets.businessinsider.comViking Therapeutics’ Promising Phase 2 Trial and Competitive Edge Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 8, 2025 | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Wednesday.January 8, 2025 | marketbeat.comViking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesityJanuary 8, 2025 | prnewswire.comViking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should KnowJanuary 7, 2025 | msn.comViking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells $2,150,709.75 in StockJanuary 7, 2025 | insidertrades.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. Eleven equities research analysts have rated the stock with a buy rating and twoJanuary 7, 2025 | marketbeat.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 50,309 Shares of StockViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 50,309 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,150,709.75. Following the transaction, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. The trade was a 23.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.January 6, 2025 | marketbeat.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells 54,215 Shares of StockViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 54,215 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the completion of the transaction, the chief operating officer now owns 374,134 shares in the company, valued at approximately $15,994,228.50. This trade represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.January 6, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian Sells 194,490 SharesViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 194,490 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the completion of the transaction, the chief executive officer now directly owns 2,366,570 shares of the company's stock, valued at $101,170,867.50. This represents a 7.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 6, 2025 | marketbeat.comViking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.com1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street AnalystsJanuary 6, 2025 | fool.comWhy Viking Therapeutics Stock Plummeted by 24% in DecemberJanuary 4, 2025 | fool.comViking Therapeutics among potential buyout candidates: OppenheimerJanuary 3, 2025 | seekingalpha.comShould You Buy the Dip on This High-Flying Stock?January 3, 2025 | fool.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 2, 2025 | prnewswire.com3 Stocks That Could Be Monster Winners in 2025December 29, 2024 | fool.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXDecember 27, 2024 | prnewswire.comWill Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?December 24, 2024 | insidermonkey.comViking Therapeutics (NASDAQ:VKTX) Trading Down 0.1% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Trading Down 0.1% - Should You Sell?December 24, 2024 | marketbeat.comPrincipal Financial Group Inc. Acquires 136,729 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Principal Financial Group Inc. raised its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 29.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 593,528 shares of the biotechnology comDecember 24, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 1.3% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Trading Down 1.3% - Here's What HappenedDecember 23, 2024 | marketbeat.comIs Viking Therapeutics, Inc. (VKTX) the Best Performing Biotech Stock in 2024?December 23, 2024 | insidermonkey.comStocks on Sale: Novo Nordisk, Viking Therapeutics, Nike, and BitcoinDecember 23, 2024 | baystreet.caIs Viking Therapeutics, Inc. (VKTX) the Best Performing Biotech Stock in 2024?December 23, 2024 | msn.comDown 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?December 21, 2024 | fool.comMy Top 10 Stocks to Buy for 2025December 21, 2024 | fool.comB.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)December 20, 2024 | markets.businessinsider.com Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Media Mentions By Week VKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼0.440.44▲Average Medical News Sentiment VKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼1416▲VKTX Articles Average Week Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Genmab A/S News Today Viatris News Today Intra-Cellular Therapies News Today Moderna News Today Dr. Reddy's Laboratories News Today Catalent News Today Sarepta Therapeutics News Today Vaxcyte News Today Qiagen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
